Literature DB >> 10869047

Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis.

S Vielhaber1, D Kunz, K Winkler, F R Wiedemann, E Kirches, H Feistner, H J Heinze, C E Elger, W Schubert, W S Kunz.   

Abstract

Amyotrophic lateral sclerosis is a neurodegenerative disease affecting the anterior horn cells of the spinal cord and cortical motor neurons. Previous findings have suggested a specific impairment of mitochondrial function in skeletal muscle of at least a limited number of patients. Applying flavoprotein/NAD(P)H autofluorescence imaging of mitochondrial function in saponin-permeabilized muscle fibres, we detected a heterogeneous distribution of the respiratory chain defect among individual fibres in muscle biopsies of patients (11 out of 17) with sporadic amyotrophic lateral sclerosis (SALS). These findings correlate with the presence of cytochrome c oxidase (COX)-negative muscle fibres detected histologically. We established the molecular basis for the decreased activities of NADH:CoQ oxidoreductase and COX in SALS muscle. In the skeletal muscle of the investigated patients, diminished levels (13 out of 17) or multiple deletions (one out of 17) of mitochondrial DNA (mtDNA) were observed. These alterations of mtDNA seem to be related to decreased levels of membrane-associated mitochondrial Mn-superoxide dismutase. Our results support the viewpoint that an oxygen radical-induced impairment of mtDNA is of pathophysiological significance in the aetiology of at least a subgroup of patients with SALS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869047     DOI: 10.1093/brain/123.7.1339

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  72 in total

Review 1.  Progress in the pathogenesis of amyotrophic lateral sclerosis.

Authors:  C E Shaw; A al-Chalabi; N Leigh
Journal:  Curr Neurol Neurosci Rep       Date:  2001-01       Impact factor: 5.081

Review 2.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  IDrugs       Date:  2010-08

Review 3.  Amyotrophic lateral sclerosis and skeletal muscle: an update.

Authors:  O Pansarasa; D Rossi; A Berardinelli; C Cereda
Journal:  Mol Neurobiol       Date:  2013-11-08       Impact factor: 5.590

Review 4.  Mitochondrial CHCHD-Containing Proteins: Physiologic Functions and Link with Neurodegenerative Diseases.

Authors:  Zhi-Dong Zhou; Wuan-Ting Saw; Eng-King Tan
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

Review 5.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Mitochondrial Disorders May Mimic Amyotrophic Lateral Sclerosis at Onset.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Sultan Qaboos Univ Med J       Date:  2016-02-02

7.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

8.  Measures of bulbar and spinal motor function, muscle innervation, and mitochondrial function in ALS rats.

Authors:  Susan E Smittkamp; Heather N Spalding; Jordan W Brown; Anisha A Gupte; Jie Chen; Hiroshi Nishimune; Paige C Geiger; John A Stanford
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

Review 9.  Shedding light on mitochondrial function by real time monitoring of NADH fluorescence: II: human studies.

Authors:  Avraham Mayevsky; Efrat Barbiro-Michaely
Journal:  J Clin Monit Comput       Date:  2012-12-08       Impact factor: 2.502

10.  Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease.

Authors:  Manoj Kumar Jaiswal; Wolf-Dieter Zech; Miriam Goos; Christine Leutbecher; Alberto Ferri; Annette Zippelius; Maria Teresa Carrì; Roland Nau; Bernhard U Keller
Journal:  BMC Neurosci       Date:  2009-06-22       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.